Overall result forecast presentation:	yes
Quantity performed reporting year:	34
Quantity forecast year:	39
Examination by state associations?	yes
Exemption?	yes
Result of the examination by the federal state authorities?	yes
Transitional arrangement?	no

Knee joint total endoprostheses

Overall result forecast presentation:	yes
Quantity performed reporting year:	147
Quantity forecast year:	160
Examination by state associations?	yes
Exemption?	yes
Result of the examination by the federal state authorities?	yes
Transitional arrangement?	no

Implementation of resolutions of the Federal Joint Committee on quality assurance (G-BA)

No.	Explanation
CQ25	Measures for quality assurance in the performance of minimally invasive heart valve interventions pursuant to Article 136, para. 1, sentence 1, number 2 for hospitals licensed in accordance with Article 108 of the SGB V
CQ05	Measures for quality assurance in the care of pre-term and full-term neonates – Perinatal Centre LEVEL 1
CQ01	Quality assurance measures for inpatient care with the indication abdominal aortic aneurysm

Compliance with staffing requirements

Clarifying chat completed: no
Clarifying chat not completed: no
No participation in clarifying chat: no
Notification of non-fulfilment of nursing care not made: yes

Further training
pursuant to Article 136b, para. 1, sentence 1, no. 1 of the SGB

Number	Group
156	Medical specialists (m/f) , psychological psychotherapists (m/f) and child and adolescent psychotherapists (m/f) who are subject to the obligation to undergo further training*
107	Number of medical specialists (m/f) from no. 1 who have completed a five-year period of further training and are therefore subject to the obligation to provide evidence
101	Number of those persons from no. 2 who have provided proof of further training according to Article 3 of the G-BA regulations

* according to the “Provisions of the Joint Federal Committee for the Further Training of Medical Specialists (m/f), Psychological Psychotherapists (m/f) and Child and Adolescent Psychotherapists (m/f) in Hospitals”

General information

Protection concept against (sexual) violence against children and young people

According to Section 4 (2) of the Quality Management Guideline, facilities must provide for the prevention of and intervention in cases of violence and abuse as part of their internal quality management. The aim is to prevent, recognise and respond appropriately to abuse and violence, particularly against vulnerable patient groups such as children and adolescents or people in need of help, and also to prevent it within the facility. The respective procedure is aligned with the size of the facility, the range of services and the patients in order to define customised solutions for sensitising the teams as well as other suitable preventative and interventional measures. These may include information materials, contact addresses, training/education, codes of conduct, recommendations for action/intervention plans or comprehensive protection concepts.

Is a protection concept in place? Yes
Note on the measure: Vorlage eines erweiterten Führungszeugnisses

Commentary on the protection concept

Gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie haben sich Einrichtungen, die Kinder und Jugendliche versorgen, gezielt mit der Prävention von und Intervention bei (sexueller) Gewalt und Missbrauch bei Kindern und Jugendlichen zu befassen (Risiko- und Gefährdungsanalyse) und – der Größe und Organisationsform der Einrichtung entsprechend – konkrete Schritte und Maßnahmen abzuleiten (Schutzkonzept). In diesem Abschnitt geben Krankenhäuser, die Kinder und Jugendliche versorgen, an, ob sie gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie ein Schutzkonzept gegen (sexuelle) Gewalt bei Kindern und Jugendlichen aufweisen.

Drug therapy safety

Steering committee

No working group set up

Training of employees on AMTS related topics

Electronic support for the admission and anamnesis process (e.g. import of patient master data or medication plans, use of a drug knowledge database, input screen for drugs or anamnesis information)

SOP on good prescription practices

VA Anordnung und Verabreichung Medikamente im stationären Setting

15.06.2021

Possibility of electronic prescription i.e. structured entry of active substances (or name of the preparation), form, dose, dose frequency (e.g. in the HIS, in prescription software)

Provision of one or more electronic drug information systems (e.g. Lauer-Taxe®, ifap klinikCenter®, Gelbe Liste®, Fachinfo-Service®)

Electronic support for the supply of patients with drugs

Vorhandensein von elektronischen Systemen zur Entscheidungsunterstützung (z.B. Meona®, Rpdoc®, AIDKlinik®, ID Medics® bzw. ID Diacos® Pharma)

Electronic documentation of the administration of drugs

Measures to minimise medication errors

Fallbesprechungen
Spezielle AMTS-Visiten (z. B. pharmazeutische Visiten, antibiotic stewardship, Ernährung)
Teilnahme an einem einrichtungsübergreifenden Fehlermeldesystem (siehe Kapitel 12.2.3.2)
Leitfaden antibiotic stewardship

Instruments and measures

The instruments and measures to promote drug therapy safety are presented with a focus on the typical procedures of the medication process in inpatient patient care. A special feature of the medication process in the inpatient environment is the transition management during admission and discharge. The instruments and measures listed below address structural elements, e.g. special IT equipment and work materials, as well as process aspects, such as work descriptions for particularly risky process steps or concepts for securing typical risk situations . In addition, proven measures to avoid or learn from medication errors can be specified. The hospital presents here which aspects it has already dealt with and which measures it has specifically implemented. The following aspects can be presented, if necessary using free text fields:
- Admission to hospital, including anamnesis
; Instruments and measures are presented for determining the old medication (drug history), the subsequent clinical assessment and the switch to the medication available in the hospital (house list), as well as for documenting both the patient's original medication and that for hospital treatment adapted medication.
- Medication process in the hospital
In this context, the following sub-processes are assumed as examples: drug history - prescription - patient information - drug delivery - drug use - documentation - therapy monitoring - result assessment. Instruments and measures for safe medication prescription can be presented, e.g. B. in terms of readability, clarity and completeness of the documentation, but also in terms of area of application, effectiveness, benefit-risk ratio, tolerability (including potential contraindications, interactions, etc.) and resource considerations. Information can also be provided to support reliable medication ordering, delivery and use or administration.
- Discharge
In particular, the measures taken by hospitals can be presented to ensure that information on drug therapy is structured and passed on to doctors and physicians providing further treatment, as well as the appropriate provision of patients with drug information, medication plans and medications. Drug prescriptions are made.

AMTS is the totality of measures to ensure an optimal medication process with the aim of reducing medication errors and thus avoidable risks for patients during drug therapy. A prerequisite for the successful implementation of these measures is that AMTS is practised as an integral part of daily routine in an interdisciplinary and multi-professional approach.

Special instrument-based equipment

Research & teaching

Job

FL04 - Project-related cooperation with colleges and universities

Explanation

Prof. Dr. Richard Berger, Prof. Dr. Carsten Maik Naumann, Dr. Walter Richter, Dr. Burkhard Hügl, Peter Wack, PD Dr. Christoph G. Wölfl, Dr. Knut Schäfer, Frau Dr. Louise Kastor (1. Neo Cam Care Studie 2020-2022 2. Neo Milk Studie seit 2023)

FL07 - Initiation and management of uni-centric/multi-centric clinical/scientific studies

Explanation

Prof. Dr. Richard Berger, Dr. Burkhard Hügl

FL05 - Participation in multi-centre Phase I/II studies

Explanation

Prof. Dr. Richard Berger

FL06 - Participation in multi-centre phase III/IV studies

Explanation

Prof. Dr. Richard Berger, Dr. Burkhard Hügl, Dr. Walter Richter

FL08 - Editors of scientific journals/textbooks

Explanation

Prof. Berger, Dr. Fresenius (Repetitorium Anästhesiologie, Repetitorium Intensivmedizin, Repetitorium Schmerztherapie), PD Dr. Wölfl (“Schwerverletztenversorgung – Diagnostik und Therapie der ersten 24 Stunden" uvm.)

FL09 - Doctoral supervision

Explanation

Prof. Dr. Richard Berger, PD Dr. Götz Lutterbey, Prof. Dr. Carsten Maik Naumann, Dr. Burkhard Hügl

FL02 - Lectureships / teaching posts at universities of applied sciences

Explanation

Dr. Walter Richter

FL03 - Student training (clinical traineeship / internship year)

Explanation

Prof. Dr. Richard Berger, Dr. Claus Schneider, PD Dr. Götz Lutterbey, Dr. Burkhard Hügl, Prof. Dr. Carsten Maik Naumann, Dr. Knut Schäfer, Dr. Walter Richter, Dr. Michael Fresenius, Peter Wack, PD Dr. Christoph Wölfl, Dr. Sven Arcan, Frau Dr. Louise Kastor, Dr. Kai Zbieranek

FL01 - Lectureships / teaching posts at colleges and universities

Explanation

Prof. Dr. Richard Berger, PD Dr. Götz Lutterbey, Dr. Claus Schneider, Dr. Michael Fresenius, Prof. Dr. Carsten Maik Naumann, Dr. Walter Richter, PD Dr. Christoph G. Wölfl

Training